Services on Demand
- Cited by SciELO
- Access statistics
- Cited by Google
- Similars in SciELO
- Similars in Google
Print version ISSN 0365-0596
On-line version ISSN 1806-4841
An. Bras. Dermatol. vol.86 no.4 supl.1 Rio de Janeiro July/Aug. 2011
Erythrodermic psoriasis with regression after prophylaxis with isoniazid and antidepressant therapy - case report*
Isabella Portela RedighieriI; Tatiana de Carvalho MaiaI Millena Accetta NadalII; Tatiana Romeu Lorenzon CalimanII; Maria de Fátima Maklouf Amorim RuizIII; Valeria PetriIV
ITrainee Physician of the Dermatology Service of the Hospital Ipiranga (HI) - Ipiranga (SP), Brasil
IIDermatologist of the Psoriasis Unit of the Escola Paulista de Medicina of the Universidade Federal de São Paulo (UNIFESP) - São Paulo (SP), Brasil
IIIDermatologist, Tutor at the Psoriasis Unit of the Escola Paulista de Medicina of the Universidade Federal de São Paulo (UNIFESP) - São Paulo (SP), Brasil
IVFull Professor of the Dermatology Department of the Escola Paulista de Medicina - Universidade Federal de São Paulo (UNIFESP) - São Paulo (SP), Brasil
An 83 year old woman, exhibiting severe psoriasis, was treated conventionally (phototherapy, acitretin, and cyclosporine). After poor clinical results and significant changes in laboratory procedures, those treatments were suspended. She was then being prepared to be submitted to biological treatment, when preliminary results disclosed a 30mm PPD. Complete improvement occurred [only] after introducing prophylactic therapy for tuberculosis and anti-depressive medication.
Keywords: Acitretin; Antidepressive agents; Cyclosporine; Isoniazid; Psoriasis; Tuberculosis
Psoriasis is a chronic immunologic disease, with genetic background and inflammatory changes, which affects the skin, the cutaneous appendages and the joints. It afflicts approximately 2% of the world population and it causes significant psychosocial damage. 1,2 Bacterial infections, medications and emotional stress are among the triggering factors. Patients resistant to the classical treatment can be offered immune biological treatment, which can lead to the control of the process. 3-8 Tuberculosis is an infection that contraindicates the use of immune biological drugs and chemoprophylaxis can work by eliminating the probable triggering agent.
White female, 83 years old, original from Ururai (SP), living in São Paulo, capital city, presented with disseminated erythematous-desquamative lesions (PASI = 7,2) for 18 months. The histopathological examination was compatible with psoriasis. She underwent phototherapy (PUVA and, afterwards, narrow band UVB, two sessions a week for 18 months), without significant improvement. She was then treated with acitretin (10mg/day), with marked improvement of the disease but with significant alterations of the hepatic enzymes. The drug was discontinued and she was treated with topical emollients and phototherapy (narrow band UVB). There was worsening of the clinical status and rise of the PASI to 14.6 (Figures 1 and 2). Besides, she had a PPD of 16 mm, which prompted a pneumologic evaluation that did not disclose active tuberculosis. Eight months after the laboratory tests normalized treatment with cyclosporine (200mg/day) started and after five months there was an improvement of the PASI (4.8). Recurrence developed slowly with the gradual reduction of the cyclosporine (50mg/week), and the initial dose was reintroduced. The dermatosis was under control for ten months when there was an alteration of the renal function. Biological treatment was indicated and the preconised screening tests revealed a PPD test of 30mm.
Active tuberculosis was excluded and prophylaxis with isoniazid, 300mg/day for six months began.1 Simultaneously the patient's depressive status was treated with sertraline (50mg/day). After 90 days of treatment there was a complete regression of the disease (Figures 3 and 4), without recurrence over the subsequent months.
Psoriasis is a common disease, with a world prevalence of around 2 to 3% and genetic predisposition, ambient aspects (traumas, lifestyle habits, and medications), infections and psychological stress are implicated on the development of the disease.9, 10,11 Treatment is individualized and should be based on the clinical presentation and severity of each case. Elimination of probable causative agents is essential and preliminary when planning the therapeutic options. Because of resistance and intolerance to conventional therapy of psoriasis, the immune biological drugs area an option capable of promoting the control of the disease, the social reinsertion and an improvement on the quality of life of the patients. 12 Tumor necrosis factor-alpha (TNF-alpha) has a central role on the physiopathology of cutaneous and arthropathic psoriasis and, at the same time, it is able to prevent primary infection of tuberculosis, avoid its reactivation and keep the causal agent latent. 13-17 There is sufficient evidence that inhibitors of TNF-alpha are related to increased numbers of active tuberculosis. 18,19 The possibility of reactivation of latent tuberculosis and rigorous screening on endemic areas should be considered.19-24 Besides, tuberculinic turning is observed with treatment with cyclosporine, a drug capable of suppressing immunity and facilitating the reactivation of latent foci or even primary infection. 22
On the present case the previous treatment with cyclosporine might have been responsible for the relative immunosupression capable of reactivating a latent focus or facilitating the development of primary tuberculosis infection. The control of the latent infectious process with chemoprophylaxis thus resulted in an improvement of the severe psoriasis, and the control of the depressive status with medication might have had an additional impact.
1. Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2009. 1th ed. Rio de Janeiro: Sociedade Brasileira de Dermatologia, 2009. p.5-115. [ Links ]
2. Kiliç A, Güleç MY, Gül U, Güleç H. Temperament and character profile of patients with psoriasis. J Eur Acad Dermatol Venereol. 2008;22:537-42. [ Links ]
3. Levine D, Gottlieb A. Evaluation and management of psoriasis: an internist's guide. Med Clin North Am. 2009;93:1291-303. [ Links ]
4. Edlich RF, Fisher AL, Chase ME, Brock CM, Gubler KD, Long WB 3rd. Modern concepts of the diagnosis and treatment of psoriasis. J Environ Pathol Toxicol Oncol. 2009;28:235-40. [ Links ]
5. Gottlieb AB, Kardos M, Yee M. Current biologic treatments for psoriasis. Dermatol Nurs. 2009;21:259-66. [ Links ]
6. Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V, Lynde C, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg. 2004;8:321-37. [ Links ]
7. van de Kerkhof PC. The relevance of biologics for the treatment of patients with ps oriasis. Br J Dermatol. 2009;161:1213-4. [ Links ]
8. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009;22:431-40. [ Links ]
9. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25:535-46. [ Links ]
10. Puig-Sanz L. Psoriasis, a sistemic disease? Actas Dermosifiliogr. 2007;98:396-402. [ Links ]
11. Krueger G, Ellis CN. Psoriasis--recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53(Suppl 1):S94-100. [ Links ]
12. Saini R, Tutrone WD, Weinberg JM. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. Curr Pharm Des. 2005;11:273-80. [ Links ]
13. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-a inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol. 2009;160:8-15. [ Links ]
14. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180-210. [ Links ]
15. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19:47-57. [ Links ] 16. Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol. 2009;8:546-59. [ Links ]
17. de Felice C, Ardigo M, Berardesca E. Biologic therapies for psoriasis. J Rheumatol Suppl. 2009;83:62-4. [ Links ]
18. Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol. 2008;59:363-80. [ Links ]
19. Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59:209-17. [ Links ]
20. Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol. 2009;161:797-800. [ Links ]
21. Hanta I, Ozbek S, Kuleci S, Sert M, Kocabas A. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. Clin Rheumatol. 2007;26:1867-70. [ Links ]
22. Ho VC. The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol. 2004;150(Suppl 67):1-10. [ Links ]
23. Bressan AL, Souto RS, Fontenelle E, Gripp AC. Imunossupressores na Dermatologia. An Bras Dermatol. 2010;85:9-22. [ Links ]
24. Arruda LHF, Rodriguez SYSD, Gladys AM. Tratamento sistêmico da psoríase - Parte II: imunomoduladores biológicos. An Bras Dermatol. 2004;79:393-408. [ Links ]
Mailing address: Received on 20.10.2010. * Work performed at: Instituto da Pele - Escola Paulista de Medicina - Universidade Federal de São Paulo (UNIFESP) - São Paulo (SP), Brasil.
Isabella Portela Redighieri
Instituto da Pele (Escola Paulista de Medicina - Universidade Federal de São Paulo)
Rua Borges Lagoa, 783 - 9º Andar Vila Clementino
04038 901 São Paulo SP, Brazil
Approved by the Advisory Board and accepted for publication on 08.12.2011.
Conflict of interest: None
Financial funding: None
Received on 20.10.2010.
* Work performed at: Instituto da Pele - Escola Paulista de Medicina - Universidade Federal de São Paulo (UNIFESP) - São Paulo (SP), Brasil.